Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
89bio, Inc. (ETNB)  
$8.86 0.11 (1.26%) as of 4:30 Thu 5/2


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 97,871,000
Market Cap: 867.14(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.66 - $22.03
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 20.2
Insider 6 Months    : 20.2
Insider 3/6 Months : 40.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,350,000 1,350,000 1,350,000 7,862,717
Total Buy Value $20,722,500 $20,722,500 $20,722,500 $80,687,796
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 5
Total Shares Sold 57,195 107,195 154,628 206,908
Total Sell Value $623,326 $1,183,326 $2,078,063 $2,842,845
Total People Sold 1 1 4 5
Total Sell Transactions 2 3 7 15
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 89
  Page 4 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Palekar Rohan Chief Executive Officer   •       •      –    2021-07-07 4 B $17.07 $85,350 D/D 5,000 35,000 2.81 9%     
   Waisbourd Ram See Remarks   •       –      –    2021-06-16 4 AS $19.67 $137,690 D/D (7,000) 0 -12%     
   Waisbourd Ram See Remarks   •       –      –    2021-06-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Shah Rajeev M. Director   –       •       •   2021-06-02 4 B $18.77 $415,530 I/I 22,138 4,965,769 2.25 -3%     
   Shah Rajeev M. Director   –       •       •   2021-05-28 4 B $18.77 $2,318,189 I/I 123,505 4,943,631 2.25 -5%     
   Shah Rajeev M. Director   –       •       •   2021-05-27 4 B $18.76 $666,637 I/I 35,535 4,820,126 2.25 -4%     
   Shah Rajeev M. Director   –       •       •   2021-05-26 4 B $18.03 $872,237 I/I 48,377 4,784,591 2.25 5%     
   Waisbourd Ram See Remarks   •       –      –    2021-05-17 4 AS $21.61 $151,270 D/D (7,000) 0 -9%     
   Waisbourd Ram See Remarks   •       –      –    2021-05-17 4 OE $1.93 $13,510 D/D 7,000 7,000     -
   Grunberg Gregory Director   –       •      –    2021-04-21 4 S $27.60 $23,460 D/D (850) 0 28%     
   Martins Ryan Chief Financial Officer   •       –      –    2021-04-19 4 AS $25.00 $250,000 D/D (10,000) 7,500 -24%     
   Martins Ryan Chief Financial Officer   •       –      –    2021-04-19 4 OE $3.11 $31,100 D/D 10,000 17,500     -
   Waisbourd Ram See Remarks   •       –      –    2021-04-16 4 AS $24.22 $169,540 D/D (7,000) 0 -25%     
   Waisbourd Ram See Remarks   •       –      –    2021-04-16 4 OE $1.93 $13,510 D/D 7,000 7,000     -
  89 Records found
  1  2  3  4    
  Page 4 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us